secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001842952-22-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics and Menarini collaborate for Phase 1b/2 trial of ONA-XR + elacestrant in ER+/PR+ HER2- mBC
--------------------------------------------------------------------------------

- Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.
- Menarini supplies elacestrant at no cost; Context sponsors and funds the study.
- Elacestrant Phase 3 showed 30% reduction in risk of progression or death vs SOC in ER+/HER2- mBC.
- 12-month PFS rate: 22% for elacestrant vs 9% for SOC in overall population.
- Preclinical data suggest dual ER and PR blockade may enhance tumor control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/0001842952-22-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000066/cntx-20220801.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer